» Articles » PMID: 34920997

Multimodality Durable Salvage of Recurrent Brain Metastases Refractory to LITT, SRS and Immunotherapy with Resection and Cesium-131 Brachytherapy: Case Report and Literature Review

Overview
Journal BMJ Case Rep
Specialty General Medicine
Date 2021 Dec 18
PMID 34920997
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Brain metastases (BrM) are treated with multimodality therapy, however the optimal combination and timing of modalities in the setting of recurrent tumours that have failed prior treatments remain poorly defined. We present a case of a patient with biopsy-confirmed renal cell carcinoma BrM with good performance status initially treated with laser interstitial thermal ablation therapy (LITT) followed by stereotactic radiosurgery and dual checkpoint inhibitor immunotherapy. He subsequently developed rapid in-field recurrence which was treated with salvage surgical resection and implantation of intracavitary cesium-131 brachytherapy. The patient's disease remained stable through 18 months postoperatively. This case illustrates the range of options available and provides a combination salvage therapy strategy in a select group of locally recurrent patients who have exhausted conventional treatment options.

Citing Articles

Laser hyperthermia: Past, present, and future.

Schupper A, Chanenchuk T, Racanelli A, Price G, Hadjipanayis C Neuro Oncol. 2022; 24(Suppl 6):S42-S51.

PMID: 36322099 PMC: 9629480. DOI: 10.1093/neuonc/noac208.


Patient-specific radiological protection precautions following Cs collagen embedded Cs-131 implantation in the brain.

Prasad K, Dauer L, Chu B, Aramburu-Nunez D, Cohen G, Beal K J Appl Clin Med Phys. 2022; 23(10):e13776.

PMID: 36109179 PMC: 9588267. DOI: 10.1002/acm2.13776.


The role of cesium-131 brachytherapy in brain tumors: a scoping review of the literature and ongoing clinical trials.

Palmisciano P, Haider A, Balasubramanian K, DAmico R, Wernicke A J Neurooncol. 2022; 159(1):117-133.

PMID: 35696019 DOI: 10.1007/s11060-022-04050-3.

References
1.
Bander E, Yuan M, Reiner A, Panageas K, Ballangrud A, Brennan C . Durable 5-year local control for resected brain metastases with early adjuvant SRS: the effect of timing on intended-field control. Neurooncol Pract. 2021; 8(3):278-289. PMC: 8153823. DOI: 10.1093/nop/npab005. View

2.
Mahase S, Navrazhina K, Schwartz T, Parashar B, Wernicke A . Intraoperative brachytherapy for resected brain metastases. Brachytherapy. 2019; 18(3):258-270. DOI: 10.1016/j.brachy.2019.01.011. View

3.
Zeeshan Ozair M, Giantini Larsen A, Eng J, Moss N . Exceptional Response of a Large and Symptomatic EGFR-Mutant Brain Metastasis to Osimertinib: Case Report and Review of the Literature. JCO Precis Oncol. 2021; 5. PMC: 8169075. DOI: 10.1200/PO.20.00485. View

4.
Soltys S, Adler J, Lipani J, Jackson P, Choi C, Puataweepong P . Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys. 2007; 70(1):187-93. DOI: 10.1016/j.ijrobp.2007.06.068. View

5.
Hong C, Deng D, Vera A, Chiang V . Laser-interstitial thermal therapy compared to craniotomy for treatment of radiation necrosis or recurrent tumor in brain metastases failing radiosurgery. J Neurooncol. 2019; 142(2):309-317. DOI: 10.1007/s11060-019-03097-z. View